A decrease in only the frequency of CD45RA+ effector memory (TEMRA) CD4 T cells and plasmablasts has been reported for patients with MS after 6 months of treatment, while the frequency of other immune cells, including CD8 T cells, remained similar before and after DHODH inhibition (9). Here, CD4 is linked to myeloid sarcoma.